Responsive image

Common name


(E,2S)-4-(4-isopropylpyrimidin-5-yl)but-3-en-2-ol

IUPAC name


(E,2S)-4-(4-isopropylpyrimidin-5-yl)but-3-en-2-ol

SMILES


C(=CC(C)O)c1c(ncnc1)C(C)C

Common name


(E,2S)-4-(4-isopropylpyrimidin-5-yl)but-3-en-2-ol

IUPAC name


(E,2S)-4-(4-isopropylpyrimidin-5-yl)but-3-en-2-ol

SMILES


C(=CC(C)O)c1c(ncnc1)C(C)C

INCHI


InChI=1S/C11H16N2O/c1-8(2)11-10(5-4-9(3)14)6-12-7-13-11/h4-9,14H,1-3H3/b5-4+/t9-/m0/s1

FORMULA


C11H16N2O

Responsive image

Common name


(E,2S)-4-(4-isopropylpyrimidin-5-yl)but-3-en-2-ol

IUPAC name


(E,2S)-4-(4-isopropylpyrimidin-5-yl)but-3-en-2-ol





Molecular weight


192.258

clogP


2.327

clogS


-2.126

Frequency


0.0003





HBond Acceptor


3

HBond Donor


1

Total Polar
Surface Area


46.01

Number of Rings


1

Rotatable Bond


3

Drug ID Common name Structure CAS Compound class Therapeutic area
FDBD00948 Rosuvastatin Responsive image Hydroxymethylglutaryl-CoA Reductase Inhibitors; HMG CoA Reductase Inhibitors; Lipid Modifying Agents, Plain; Lipid Modifying Agents; Cardiovascular System; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C19 Inducers; CYP3A4 Inhibitors; Used as an adjunct to dietary therapy to treat primary hyperlipidemia (heterozygous familial and nonfamilial), mixed dyslipidemia and hypertriglyceridemia. Also indicated for homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering therapies or when other such therapies are not available. Furthermore, it is used to slow the progression of atherosclerosis and for primary prevention of cardiovascular disease.
1 , 1
FRAGNAME PDBID SIMILIRITY XSCORE SMILE HAC
4nah_ligand_1_0.mol2 4nah 0.552239 -5.99 c1(ccncn1)CC 8
4nau_ligand_1_0.mol2 4nau 0.552239 -5.93 C(C)c1ccncn1 8
3ith_ligand_1_2.mol2 3ith 0.552239 -5.57 c1cc(ncn1)CC 8
2il2_ligand_1_3.mol2 2il2 0.527027 -6.42 n1ccc(nc1N)CC 9
4myq_ligand_1_1.mol2 4myq 0.514286 -6.77 c1nc(c(cn1)CC)C 9
4g2w_ligand_2_20.mol2 4g2w 0.511628 -6.86 C(C)c1c(CC)nc[nH]c1=O 11
101 , 11